# Enveric Biosciences, Inc.: Form 10-Q for the period ended Jun 30, 2011

- Company: [Enveric Biosciences, Inc.](/companies/envb.md) (CIK 890821)
- Form: 10-Q
- Filed: 2011-08-02
- Accepted by EDGAR: Aug 2, 2011, 15:02 ET
- Period: 2011-06-30
- Accession: 0001477932-11-001265
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/890821/000147793211001265/spzr_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/890821/000147793211001265/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2011-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Cost of revenue | 3 months, 2011-04-01 to 2011-06-30 | $0 | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2011-01-01 to 2011-06-30 | $0 | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2011-04-01 to 2011-06-30 | $0 | us-gaap:GrossProfit |
| Gross profit | 6 months, 2011-01-01 to 2011-06-30 | $0 | us-gaap:GrossProfit |
| Research and development | 3 months, 2011-04-01 to 2011-06-30 | $0 | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2011-01-01 to 2011-06-30 | $0 | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2011-04-01 to 2011-06-30 | −$3.6k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2011-01-01 to 2011-06-30 | −$14.7k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2011-04-01 to 2011-06-30 | $0 | us-gaap:InterestExpense |
| Interest expense | 6 months, 2011-01-01 to 2011-06-30 | $0 | us-gaap:InterestExpense |
| Income tax | 3 months, 2011-04-01 to 2011-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2011-01-01 to 2011-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2011-04-01 to 2011-06-30 | −$3.6k | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2011-01-01 to 2011-06-30 | −$14.7k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2011-04-01 to 2011-06-30 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months, 2011-01-01 to 2011-06-30 | $2.7k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2011-06-30 | $3.8k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2011-06-30 | $3.1k | us-gaap:AssetsCurrent |
| Total assets | at 2011-06-30 | $8.1k | us-gaap:Assets |
| Current liabilities | at 2011-06-30 | $72.3k | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2011-06-30 | −$64.2k | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/890821/000147793211001265/spzr_10q.htm

Filed Aug 2, 2011.
Source: SEC EDGAR, the filing index for accession 0001477932-11-001265. Last ingested by Listed: Nov 14, 2026, 20:02 ET. No prices; not investment advice.
